Board MeetingOutcome of Board Meeting

Morepen Labs approved consolidated financial results for FY26 with a net profit of Rs 94.88 Cr.

Morepen Laboratories Limited logo
Morepen Laboratories LimitedMOREPENLAB · Filed with the exchange

A final dividend of Re 0.20/share was proposed.

The board also approved a revised agreement to hive off its Medical Devices business to a subsidiary for Rs 197.10 Cr and re-appointed Cost Auditors.

Read the original filing(PDF)

No comments yet. Be the first.

More from Morepen Laboratories Limited

All announcements